Research in the department of pharmacotherapy and translational research primarily focuses on understanding genetic and nongenetic factors that contribute to variability in drug response. The department has nearly two dozen faculty leading research initiatives at all three UF College of Pharmacy campuses in Gainesville, Jacksonville and Orlando.
Areas of Research
Precision Medicine / Implementation Science
Pharmacogenomics
Cardiovascular
Clinical Pharmacology / Drug Metabolism
Infectious Diseases
Oncology
Systems Pharmacology
Educational Research
Research Faculty
Professor And The Perry E. Foote Eminent Scholar Chair
Jürgen Bulitta, Ph.D.
PROFESSOR AND THE DEBBIE DESANTIS TERM PROFESSOR IN THE UF COLLEGE OF PHARMACY
Larisa Cavallari, Pharm.D.
* Effectiveness of cardiovascular drugs
* Dose requirements of warfarin
* Opioid effectiveness and toxicity
* Drug metabolism enzyme activity and expression
* Outcomes with clinical implementation of genotype-guided therapy
CLINICAL ASSOCIATE PROFESSOR
Emily Cicalli, Pharm.D.
* Drug metabolism enzyme activity and expression
* Outcomes with clinical implementation of genotype-guided therapy
RESEARCH ASSISTANT PROFESSOR
Joseph Collins, Ph.D.
* Epigenetic and genetic variation contributing to differences in pharmacogene expression
* Computational approaches to utilize public datasets for variant discovery and validation
clinical professor
David DeRemer, Pharm.D.
* Cancer treatment outcomes
* Cardiotoxic response to cancer treatments (Cardio-Oncology)
ASSOCIATE PROFESSOR
Julio Duarte, Pharm.D., Ph.D.
* Effectiveness of cardiovascular drugs
* Genomics to identify novel drug targets for cardiopulmonary diseases
* Outcomes with clinical implementation of genotype-guided therapy
ASSISTANT PROFESSOR
Mohammed Gbadamosi, Ph.D.
* Personalized medicine
* Immuno-oncology
* Cancer disparities
* Metastatic cancer
* Big data analytics
ASSOCIATE professor
Yang Gong, Ph.D.
* Effectiveness of cardiovascular drugs
* Cardiotoxic response to cancer treatments (Cardio-Oncology)
* Adverse drug response to antiresorptive drugs
ASSOCIATE DEAN FOR RESEARCH AND GRADUATE EDUCATION; PROFESSOR AND THE FRANK A. DUCKWORTH EMINENT SCHOLAR CHAIR
Jatinder Lamba, Ph.D., M.Sc.
* Cancer treatment outcomes
* Toxicity to anti-leukemic agents
* CRISPR/cas9 mediated genetic perturbation screening in cancer
* Development of genomics guided immunotherapy for treatment of leukemia
* Systems biology approaches using multi-dimensional data to establish prognostic markers in cancer
research assistant professor
Yinzhi Lang, Ph.D.
* Mechanistic assays to decode drug actions and resistance mechanisms
* UPLC-MS/MS for drug target site analysis and Quantitative and Systems Pharmacology (QSP) modeling
* Population pharmacokinetics/pharmacodynamics studies of anti-infective agents
* LC-MS/MS techniques for advanced glycomics and proteomics
professor
John Markowitz, Pharm.D.
* Drug metabolism enzyme activity and expression
* Drug transporter activity
assistant professor
Caitrin McDonough, Ph.D., M.S.
* Effectiveness of cardiovascular drugs
* Predisposition to adverse cardiovascular and cerebrovascular outcomes and high risk disease
* Development of multi-dimensional data models for cardiovascular disease identification and prediction
* Development of multi-dimensional data models for Alzheimer’s Disease and Related Dementias
clinical assistant professor
Khoa Nguyen, Pharm.D.
* Effectiveness of cardiovascular drugs
* Opioid effectiveness and toxicity
* Outcomes with clinical implementation of genotype-guided therapy
Professor And The Jack C. Massey Professor
Charles Peloquin, Pharm.D.
RESEARCH ASSISTANT PROFESSOR
Alaa R. M. Sayed, Ph.D.
clinical assistant professor
Nathan Seligson, Pharm.D.
* Cancer treatment options
* Systems biology approaches using multi-dimensional data to establish prognostic markers in cancer
Research Assistant Professor
Vivek Shastri, Ph.D.
* Identification, characterization, and validation of pharmacogenomic markers to predict response to therapy in acute myeloid leukemia, or AML, patients
* Developing and evaluating novel agents targeting CD33 isoforms to benefit AML patients not responding to currently available immunotherapy options
RESEARCH ASSISTANT PROFESSOR
Marwa Tantawy, Ph.D.
* Cardiotoxic response in cancer treatment (Cardio-oncology)
* Pharmacogenomics and personalized medicine
* iPSC differentiation for mechanistic insights into cardiovascular complications
Clinical Associate Professor
Katie Vogel Anderson, Pharm.D.
* Evaluating student pharmacist success before and after the change in the PCAT requirement
* Patient education programs for pharmacogenomic testing
ASSOCIATE PROFESSOR
Danxin Wang, M.D., Ph.D.
* Drug metabolism enzyme activity and expression
Established in 2001
Center for Pharmacogenomics and Precision Medicine
Research in the Center for Pharmacogenomics and Precision Medicine strives to identify genetic variations that affect drug response, with the goal of enabling safer and more effective drug therapy.
